Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 2, 2012, Pages 257-258

  Konsta, M ^a   Rallis, E ^a   Karameris, A ^a   Stratigos, A ^a   Sfikakis, P P ^a   Iliopoulos, A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT;

ADULT; CASE REPORT; CLINICAL FEATURE; ERYTHEMA; FEMALE; HUMAN; HYPERKERATOSIS; LETTER; MALE; NAIL DISEASE; ONYCHOLYSIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOCONJUGATES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PSORIASIS; T-LYMPHOCYTES;

EID: 84856342890     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04042.x     Document Type: Letter

References (10)

1. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 2006; 65 (Suppl. 3): iii2-iii15. (Pubitemid 44629094)
2. Mease P, Genovese M, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a doubleblind, randomized, placebo-controlled phase 2 trial. Arthritis Rheum 2010; Dec 2 [Epub ahead of print]
3. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243-1252. (Pubitemid 29218294)
4. Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192: 681-694.
5. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005; 52: 2513-2518. (Pubitemid 41117439)
6. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 2006; 65: 405-407. (Pubitemid 43268235)
7. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209-215.
8. Sibilia J, Westhovens R,. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: S46-S56. (Pubitemid 350167905)
9. Florent A, Albert C, Giacchero D, et al. Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy. Joint Bone Spine 2010; 77: 626-627.
10. Storage SS, Agrawal H, Furst DE,. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med 2010; 25: 1-17.